Male
Multidisciplinary Team(s)
Breast Cancer
Head Neck Oncology
Thoracic Oncology
Department/Research Program(s)
Department of Oncology
Cancer Type(s)
Ear Cancer
Eye Cancer
Nose Cancer
Neck Cancer
Oral Cavity Cancer (Mouth)
Lung Cancer (Small Cell Non-Small Cell)
Esophageal Cancer
Breast cancer
Contact Info
Email:
sukaria@karmanos.org
来自 http://www.karmanos.org/physicians/Ammar-Sukari?Disease=197PageIndex=0SortDirection=1
Education
Fellowship
Medical Oncology, William Beaumont Hospital, Royal Oak, MI
Medical School
University of Aleppo Medical School
Residency
Internal Medicine, William Beaumont Hospital Royal Oak, MI
Professional Memberships/Associations
American Society of Clinical Oncology
Michigan State Medical Society
Syrian Physicians Association
Board Certifications
American Board of Internal Medicine
Medical Oncology
Clinical Interests
Medical Oncologist
Profile
Ammar Sukari, M.D., is a medical oncologist and member of the Head and Neck and Thoracic Multidisciplinary Teams at the Karmanos Cancer Center. He is also an assistant professor of internal medicine at Wayne State University School of Medicine. Dr. Sukari received a medical diploma from the University of Aleppo Medical School in Syria. He completed his first year residency in internal medicine at Al Assad University Hospital in Syria. Dr. Sukari also completed an internal medicine residency and medical oncology fellowship at William Beaumont Hospital in Royal Oak, MI. Dr. Sukari is board certified by the American Board of Medical oncology and the American Board of Internal Medicine. He is also a member of the American Society of Clinical Oncology, American Medical Association and the Michigan State Medical Society. Dr. Sukari joined the Karmanos Cancer Center in 2008.
Publications
Nodal pathologic features are prognostic in head and neck cancer patients undergoing chemoradiotherapy, Head Neck, In Press. Authors: Christensen M, Paximadis P, Dyson G, Kamdar D, Sukari A, Lin HS, Yoo GH, Kim H,
Concurrent Chemoradiotherapy Improves Survival in Patients with Hypopharyngeal Cancer, International Journal of Radiation Oncology, In Press. Authors: Paximadis P, Yoo GH, Lin HS, Jacobs J, Sukari A, Dyson G, Christinsen M, Kim H,
L-00254-2011, MDM2 inhibitor MI-219-Cisplatin Induces Apoptosis in Lung Cancer Cells Irrespective of the Mutational Status of p53 has been submitted to American Journal of Physiology - Lung Cellular and Molecular Physiology on 1st Aug 2011. Authors: ASFAR AZMI, Ammar Sukari, Mai'n Maitah, Amanda Sehmer, and Ramzi Mohammad
A phase II study examining the feasibility of long term use of low dose oral capecitabine (Xeloda) in the adjuvant setting following definitive therapy in patients with newly diagnosed head and neck squamous cell carcinoma (manuscript in progress). Authors: Sukari A, Abrams J, Kafri Z, Almhanna K, Ensley JF, Kucuk O, KimH, Mulrenan H, Lin HS, Yoo GH,
Phase II Study of Docetaxel and Gemcitabine Combination in Patients with Previously Treated Recurrent or metastatic Squamous Cell Carcinoma of The Head and Neck (manuscript in progress). Authors: Kafri K, Sukari A, Yoo GH, Jacobs J, Kim H, Mulrenan H, Heilbrun LK, Smith D, Kucuk O,
